The data generated by the International FTD-Genomics Consortium (IFGC) are available upon request to protect patient information and can be accessed at---<https://ifgcsite.wordpress.com/data-access/>. The data contained within the National Institute on Aging Genetics of Alzheimer\'s Disease Data Storage (NIAGADS)---<https://www.niagads.org/datasets/ng00045>, UK Brain Expression Consortium (Braineac)---<http://braineac.org>, Project MinE data browser---<http://databrowser.projectmine.com>, and Gene Expression Omnibus (GEO) database---<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13162> are publicly available.

Introduction {#sec007}
============

Frontotemporal dementia (FTD) is a fatal neurodegenerative disorder and the leading cause of dementia among individuals younger than 65 years of age \[[@pmed.1002487.ref001]\]. Given rapid disease progression and the absence of disease-modifying therapies, there is an urgent need to better understand FTD pathobiology to accelerate development of novel preventive and therapeutic strategies.

Converging molecular, cellular, genetic, and clinical evidence suggests that neuroinflammation plays a role in FTD pathogenesis. Complement factors and activated microglia, key components of inflammation, have been established as histopathologic features in brains of patients \[[@pmed.1002487.ref002]\] and in mouse models of FTD \[[@pmed.1002487.ref003],[@pmed.1002487.ref004]\]. Genome-wide association studies (GWASs) have shown that single nucleotide polymorphisms (SNPs) within the immune-regulating *human leukocyte antigen* (*HLA)* region on Chromosome (Chr) 6 are associated with elevated FTD risk \[[@pmed.1002487.ref005]\]. Importantly, there is increased prevalence of immune-mediated diseases among patients with FTD \[[@pmed.1002487.ref006],[@pmed.1002487.ref007]\]. Together, these findings suggest that immune-related mechanisms may contribute to and potentially drive FTD pathology.

Recent work in human molecular genetics has emphasized "pleiotropy," where variations in a single gene can affect multiple, seemingly unrelated phenotypes \[[@pmed.1002487.ref008]\]. In the present study, we systematically evaluated genetic pleiotropy between FTD and immune-mediated diseases. Using large neurodegenerative GWASs and recently developed tools to estimate polygenic pleiotropy, we sought to identify SNPs *jointly* associated with FTD-related disorders \[[@pmed.1002487.ref009],[@pmed.1002487.ref010]\]---namely, FTD, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and amyotrophic lateral sclerosis (ALS)---and 1 or more immune-mediated diseases including Crohn disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), type 1 diabetes (T1D), celiac disease (CeD), and psoriasis (PSOR).

Methods {#sec008}
=======

Participant samples {#sec009}
-------------------

We conducted a meta-analysis of summary data obtained from published data. More specifically, we evaluated complete GWAS results in the form of summary statistics (*p*-values and odds ratios) for FTD, CBD, PSP, and ALS and 6 immune-mediated diseases, including CD \[[@pmed.1002487.ref011]\], UC \[[@pmed.1002487.ref012]\], RA \[[@pmed.1002487.ref013]\], T1D \[[@pmed.1002487.ref014]\], CeD \[[@pmed.1002487.ref015]\], and PSOR \[[@pmed.1002487.ref016]\] (see [Table 1](#pmed.1002487.t001){ref-type="table"}). We obtained FTD GWAS summary statistic data from phase I of the International FTD-Genomics Consortium (IFGC), which consisted of 2,154 clinical FTD cases and 4,308 controls with genotyped and imputed data at 6,026,384 SNPs ([Table 1](#pmed.1002487.t001){ref-type="table"}; for additional details, see \[[@pmed.1002487.ref005]\]). The FTD dataset included multiple clinically diagnosed FTD subtypes: behavioral variant (bvFTD), semantic dementia (sdFTD), primary nonfluent progressive aphasia (pnfaFTD), and FTD overlapping with motor neuron disease (mndFTD). These FTD cases and controls were recruited from 44 international research groups and diagnosed according to the Neary criteria \[[@pmed.1002487.ref017]\]. The institutional review boards of all participating institutions approved the procedures for all IFGC sub-studies. Written informed consent was obtained from all participants or surrogates. We obtained CBD GWAS summary statistic data from 152 CBD cases and 3,311 controls at 533,898 SNPs ([Table 1](#pmed.1002487.t001){ref-type="table"}; for additional details, see \[[@pmed.1002487.ref018]\]). The CBD cases were collected from 8 institutions, and controls were recruited from the Children's Hospital of Philadelphia. CBD was neuropathologically diagnosed using the National Institutes of Health Office of Rare Diseases Research criteria \[[@pmed.1002487.ref019]\]. The institutional review boards of all participating institutions approved the procedures for CBD GWAS data. Written informed consent was obtained from all participants or surrogates. We obtained PSP GWAS summary statistic data (stage 1) from the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS, [https://www.niagads.org](https://www.niagads.org/)) for 1,114 individuals with autopsy-confirmed PSP and 3,247 controls at 531,451 SNPs ([Table 1](#pmed.1002487.t001){ref-type="table"}; for additional details, see \[[@pmed.1002487.ref020]\]). The institutional review boards of all participating institutions approved the procedures for all NIAGADS sub-studies. Written informed consent was obtained from all participants or surrogates. We obtained ALS GWAS summary statistic data from 12,577 ALS cases and 23,475 controls at 18,741,501 SNPs ([Table 1](#pmed.1002487.t001){ref-type="table"}; for additional details, see \[[@pmed.1002487.ref021]\]). The ALS GWAS summary statistics and sequenced variants are publicly available through the Project MinE Data Browser ([http://databrowser.projectmine.com](http://databrowser.projectmine.com/)). The institutional review boards of all participating institutions approved the procedures for all ALS GWAS sub-studies. Written informed consent was obtained from all participants or surrogates.

10.1371/journal.pmed.1002487.t001

###### Summary data from all genome-wide association studies used in the current study.

![](pmed.1002487.t001){#pmed.1002487.t001g}

  Disorder/disease                 Abbreviation   Total *N*   Number of SNPs   Reference
  -------------------------------- -------------- ----------- ---------------- ----------------------------
  Frontotemporal dementia          FTD            6,462       6,026,384        \[[@pmed.1002487.ref005]\]
  Corticobasal degeneration        CBD            3,463       533,898          \[[@pmed.1002487.ref018]\]
  Progressive supranuclear palsy   PSP            4,361       531,451          \[[@pmed.1002487.ref020]\]
  Amyotrophic lateral sclerosis    ALS            36,052      18,741,501       \[[@pmed.1002487.ref021]\]
  Crohn disease                    CD             51,109      942,858          \[[@pmed.1002487.ref011]\]
  Ulcerative colitis               UC             26,405      1,273,589        \[[@pmed.1002487.ref012]\]
  Rheumatoid arthritis             RA             25,708      2,554,714        \[[@pmed.1002487.ref013]\]
  Type 1 diabetes                  T1D            16,559      841,622          \[[@pmed.1002487.ref014]\]
  Celiac disease                   CeD            15,283      528,969          \[[@pmed.1002487.ref015]\]
  Psoriasis                        PSOR           7,484       1,121,166        \[[@pmed.1002487.ref016]\]

Genetic enrichment statistical analyses {#sec010}
---------------------------------------

The pleiotropic enrichment strategies implemented here were derived from previously published stratified false discovery rate (FDR) methods \[[@pmed.1002487.ref022],[@pmed.1002487.ref023]\]. For given phenotypes A and B, pleiotropic "enrichment" between phenotype A and phenotype B exists if the proportion of SNPs or genes associated with phenotype A increases as a function of increased association with phenotype B. To assess for enrichment, we constructed fold enrichment plots of nominal −log10(*p*)-values for all FTD-related-disorder SNPs and for subsets of SNPs determined by the significance of their association with the 6 immune-mediated diseases. In fold enrichment plots, the presence of enrichment is reflected as an upward deflection of the curve for phenotype A with increasing strength of association with phenotype B. To assess for polygenic effects below the standard GWAS significance threshold, we focused the fold enrichment plots on SNPs with nominal −log10(*p*) \< 7.3 (corresponding to *p* \> 5 × 10^−8^). The enrichment seen can be directly interpreted in terms of the true discovery rate (1 − FDR).

To identify specific loci jointly involved with each of the 4 FTD-related disorders and the 6 immune-mediated diseases, we computed conjunction FDRs. The conjunction FDR is a test of association between 2 traits \[[@pmed.1002487.ref022]\]. Briefly, the conjunction FDR, denoted by FDR~trait1&\ trait2~, is defined as the posterior probability that a SNP is null for either trait or for both simultaneously, given that the *p*-values for both traits are as small, or smaller, than the observed *p*-values. Unlike the conditional FDR, which ranks disease/primary-phenotype-associated SNPs based on genetic "relatedness" with secondary phenotypes \[[@pmed.1002487.ref024]\], the conjunction FDR minimizes the possibility/likelihood of a single phenotype driving the common association signal. The conjunction FDR therefore tends to be more conservative and specifically pinpoints pleiotropic loci shared between the traits/diseases of interest. We used an overall FDR threshold of \<0.05, which means 5 expected false discoveries per 100 reported. To visualize the results of our conjunction FDR analysis, we constructed Manhattan plots to illustrate the genomic location of the pleiotropic loci. We ranked all SNPs based on the conjunction FDR and removed SNPs in linkage disequilibrium (*r*^2^ \> 0.2) with any higher ranked SNP. Key aspects and detailed information on fold enrichment plots, Manhattan plots, and conjunction FDRs can be found in prior reports \[[@pmed.1002487.ref022],[@pmed.1002487.ref023],[@pmed.1002487.ref025],[@pmed.1002487.ref026]\].

Functional evaluation of shared risk loci {#sec011}
-----------------------------------------

To assess whether SNPs that are shared between FTD and immune-mediated disease modify gene expression, we identified *cis*-expression quantitative trait loci (*cis*-eQTLs, defined as variants within 1 Mb of a gene's transcription start site) associated with shared FTD--immune SNPs and measured their regional brain expression in a publicly available dataset of normal control brains (UK Brain Expression Consortium; <http://braineac.org/>) \[[@pmed.1002487.ref027]\]. We also evaluated *cis*-eQTLs using a blood-based dataset \[[@pmed.1002487.ref028]\]. We applied an analysis of covariance (ANCOVA) to test for associations between genotypes and gene expression. We tested SNPs using an additive model.

Network-based functional association analyses {#sec012}
---------------------------------------------

To evaluate potential protein and genetic interactions, co-expression, co-localization, and protein domain similarity for the functionally expressed (i.e., with significant *cis*-eQTLs) pleiotropic genes, we used GeneMANIA ([http://genemania.org](http://genemania.org/)), an online web portal for bioinformatic assessment of gene networks \[[@pmed.1002487.ref029]\]. In addition to visualizing the composite gene network, we also assessed the weights of individual components within the network \[[@pmed.1002487.ref030]\].

Gene expression alterations in FTD brains {#sec013}
-----------------------------------------

To determine whether functionally expressed (i.e., with significant *cis*-eQTLs) pleiotropic genes are differentially expressed in the brains of FTD patients, we analyzed the gene expression of pleiotropic genes. Postmortem expression data from the brains of 17 patients with frontotemporal lobar degeneration with ubiquitinated inclusions (FTD-U) (with and without progranulin *\[GRN\]* mutations) and 11 controls were obtained from a publically available dataset (Gene Expression Omnibus \[GEO\] dataset GSE13162; for additional details, see \[[@pmed.1002487.ref031]\]). These data consist of global gene expression profiles from all histopathologically available regions from human FTD-U and control brains (frontal cortex, hippocampus, and cerebellum) analyzed on the Affymetrix U133A microarray platform. Given the small sample size of each individual region, we combined all 3 regions to maximize statistical power. Details about this dataset and analysis---including the human brain samples used, RNA extraction and hybridization methods, microarray quality control, and microarray data analysis---are provided in the original report \[[@pmed.1002487.ref031]\].

Evaluation of cell classes within the brain {#sec014}
-------------------------------------------

Using a publicly available RNA-sequencing transcriptome and splicing database \[[@pmed.1002487.ref032]\], we ascertained whether the functionally expressed (i.e., with significant *cis*-eQTLs) pleiotropic genes were expressed by specific cell classes within the brain. The 8 cell types surveyed were neurons, fetal and mature astrocytes, oligodendrocyte precursor cells, newly formed oligodendrocytes, myelinating oligodendrocytes, microglia/macrophages (henceforth "microglia"), endothelial cells, and pericytes (for additional details, see \[[@pmed.1002487.ref032]\]).

Results {#sec015}
=======

Shared genetic risk between FTD and immune-mediated disease {#sec016}
-----------------------------------------------------------

Using progressively stringent *p*-value thresholds for FTD SNPs (i.e., increasing values of nominal −log~10~\[*p*\]), we observed genetic enrichment for FTD as a function of several immune-mediated diseases ([Fig 1](#pmed.1002487.g001){ref-type="fig"}). More specifically, we found strong (up to 270-fold) genetic enrichment between FTD and RA, and comparable enrichment between FTD and UC, T1D, and CeD, with weaker enrichment between FTD and PSOR and CD.

![Fold enrichment plots of enrichment versus nominal −log~10~(*p*)-values (corrected for inflation) in frontotemporal dementia (FTD) below the standard genome-wide association study threshold of *p* \< 5 × 10^−8^ as a function of significance of association with 6 immune-mediated diseases.\
The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of −log~10~(*p*) \> 0, −log~10~(*p*) \> 1, and −log~10~(*p*) \> 2 correspond to *p* \< 1, *p* \< 0.1, and *p* \< 0.01, respectively. The dark blue line indicates all SNPs.](pmed.1002487.g001){#pmed.1002487.g001}

At a conjunction FDR *\<* 0.05, we identified 21 SNPs that were associated with both FTD and immune-mediated diseases ([Fig 2](#pmed.1002487.g002){ref-type="fig"}; [Table 2](#pmed.1002487.t002){ref-type="table"}). Five of these SNPs demonstrated the opposite direction of allelic effect between FTD and the immune-mediated diseases ([Table 2](#pmed.1002487.t002){ref-type="table"}): (1) rs9261536, nearest gene = *TRIM15*; (2) rs3094138, nearest gene = *TRIM26*; (3) rs9268877, nearest gene = *HLA-DRA*; (4) rs10484561, nearest gene = *HLA-DQB1*; and (5) rs2269423, nearest gene = *AGPAT1*. Of the remaining 16, 2 SNPs showed strong linkage disequilibrium (LD), suggesting that they reflected the same signal: rs204991 and rs204989 (nearest gene: *GPSM3*; pairwise *D*′ = 1, *r*^2^ = 1). After excluding SNPs that demonstrated the opposite direction of allelic effect and SNPs that were in LD, we found that 8 of the remaining 15 identified loci mapped to the *HLA* region, suggesting that *HLA* markers were critical in driving our results. To test this hypothesis, we repeated our enrichment analysis after removing all SNPs in LD with *r*^2^ \> 0.2 within 1 Mb of *HLA* variants (based on 1000 Genomes Project LD structure). After removing *HLA* SNPs, we saw considerable attenuation of genetic enrichment in FTD as a function of immune-mediated disease ([Fig 3](#pmed.1002487.g003){ref-type="fig"}), suggesting that the observed overlap between immune-related diseases and FTD was largely driven by the *HLA* region. Further, to determine causal associations for FTD and the 6 immune-mediated diseases, we applied the recently developed summary-data-based Mendelian randomization (SMR; <http://cnsgenomics.com/software/smr/>) method. This approach is described in detail within the original report \[[@pmed.1002487.ref033]\]. As shown in [S1 Table](#pmed.1002487.s011){ref-type="supplementary-material"}, results from the SMR analysis have identified significant loci that are consistent with the main findings, which suggest that *HLA* markers on Chr 6 are critical in driving our pleiotropic results.

!["Conjunction" Manhattan plot of conjunction −log~10~(FDR) values for frontotemporal dementia (FTD) given 6 immune-mediated diseases.\
The 6 immune-related diseases were Crohn disease (CD; FTD\|CD, red), ulcerative colitis (UC, FTD\|UC, orange), type 1 diabetes (T1D, FTD\|T1D, teal), rheumatoid arthritis (RA, FTD\|RA, green), celiac disease (CeD, FTD\|CeD, magenta), and psoriasis (PSOR, FTD\|PSOR, blue). SNPs with conjunction −log~10~(FDR) \> 1.3 (i.e., FDR \< 0.05) are shown with large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each locus.](pmed.1002487.g002){#pmed.1002487.g002}

![Fold enrichment plots of enrichment (after removing all regions in linkage disequilibrium with *HLA* on Chromosome 6) versus nominal −log~10~(*p*)-values (corrected for inflation) in frontotemporal dementia (FTD) below the standard genome-wide association study threshold of *p* \< 5 × 10^−8^ as a function of significance of association with 6 immune-mediated diseases.\
The 6 immune-mediated diseases were Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of −log~10~(*p*) \> 0, −log~10~(*p*) \> 1, and −log~10~(*p*) \> 2 correspond to *p* \< 1, *p* \< 0.1, and *p* \< 0.01, respectively. The dark blue line indicates all SNPs.](pmed.1002487.g003){#pmed.1002487.g003}

10.1371/journal.pmed.1002487.t002

###### Overlapping loci between FTD and immune-mediated disease at a conjunction FDR \< 0.05.

![](pmed.1002487.t002){#pmed.1002487.t002g}

  SNP          Chr   Nearest gene   Reference immune disease   Reference immune disease *p*-value   Minimum conjunction FDR   FTD *p*-value   Direction of allelic effect
  ------------ ----- -------------- -------------------------- ------------------------------------ ------------------------- --------------- -----------------------------
  rs2269423    6     *AGPAT1*       CeD                        4.63 × 10^−2^                        4.63 × 10^−2^             6.28 × 10^−1^   +/−
  rs3117097    6     *BTNL2*        RA                         8.21 × 10^−5^                        8.21 × 10^−5^             7.19 × 10^−3^   +/+
  rs204989     6     *GPSM3*        UC                         2.90 × 10^−2^                        9.02 × 10^−3^             2.58 × 10^−1^   +/+
  rs204991     6     *GPSM3*        T1D                        1.00 × 10^−2^                        9.02 × 10^−3^             2.58 × 10^−1^   +/+
  rs17427887   6     *HLA-DQA2*     RA                         3.70 × 10^−2^                        3.70 × 10^−2^             6.02 × 10^−1^   −/−
  rs10484561   6     *HLA-DQB1*     T1D                        1.86 × 10^−2^                        1.71 × 10^−2^             4.17 × 10^−1^   −/+
  rs3135353    6     *HLA-DRA*      CD                         2.29 × 10^−2^                        3.58 × 10^−3^             1.35 × 10^−1^   +/+
  rs9268852    6     *HLA-DRA*      UC                         1.25 × 10^−7^                        1.25 × 10^−7^             1.03 × 10^−4^   +/+
  rs3129890    6     *HLA-DRA*      T1D                        5.54 × 10^−5^                        5.54 × 10^−5^             7.19 × 10^−3^   +/+
  rs6457590    6     *HLA-DRA*      RA                         1.52 × 10^−2^                        1.52 × 10^−2^             3.80 × 10^−1^   +/+
  rs9268877    6     *HLA-DRA*      RA                         3.64 × 10^−7^                        1.25 × 10^−7^             1.03 × 10^−4^   +/−
  rs875142     6     *PAQR8*        CD                         4.62 × 10^−2^                        4.62 × 10^−2^             5.51 × 10^−1^   −/−
  rs9261536    6     *TRIM15*       T1D                        4.31 × 10^−2^                        4.31 × 10^−2^             6.98 × 10^−1^   −/+
  rs3094138    6     *TRIM26*       T1D                        4.63 × 10^−2^                        2.87 × 10^−2^             6.28 × 10^−1^   −/+
  rs7778450    7     *TNS3*         CeD                        4.26 × 10^−2^                        4.26 × 10^−2^             6.17 × 10^−1^   −/−
  rs2192493    7     *TWISTNB*      T1D                        4.17 × 10^−2^                        4.17 × 10^−2^             6.09 × 10^−1^   +/+
  rs10216900   8     *CR590356*     T1D                        3.09 × 10^−2^                        3.09 × 10^−2^             6.40 × 10^−1^   +/+
  rs10784359   12    *SLC2A13*      RA                         3.33 × 10^−2^                        3.33 × 10^−2^             5.90 × 10^−1^   +/+
  rs17572851   17    *MAPT*         T1D                        2.47 × 10^−2^                        2.47 × 10^−2^             5.90 × 10^−1^   +/+
  rs199533     17    *NSF*          CD                         3.90 × 10^−2^                        1.95 × 10^−2^             4.56 × 10^−1^   +/+
  rs2134297    18    *DCC*          CeD                        3.11 × 10^−2^                        3.11 × 10^−2^             5.73 × 10^−1^   +/+

CD, Crohn disease; CeD, celiac disease; Chr, Chromosome; FDR, false discovery rate; FTD, frontotemporal dementia; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism; T1D, type 1 diabetes; UC, ulcerative colitis; −, negative effect estimate; +, positive effect estimate.

Outside the *HLA* region, we found 7 other FTD- and immune-associated SNPs ([Fig 2](#pmed.1002487.g002){ref-type="fig"}; [Table 2](#pmed.1002487.t002){ref-type="table"}), including 2 in strong LD that mapped to the H1 haplotype of *microtubule associated protein tau (MAPT)* (LD: rs199533 and rs17572851; nearest genes: *NSF* and *MAPT*, pairwise *D′* = 1, *r*^2^ = 0.94). Beyond *MAPT*, we found 5 additional novel loci associated with increased FTD risk, namely, (1) rs2192493 (Chr 7, nearest gene = *TWISTNB*), (2) rs7778450 (Chr 7, nearest gene = *TNS3*), (3) rs10216900 (Chr 8, nearest gene = *CR590356*), (4) rs10784359 (Chr 12, nearest gene = *SLC2A13*), and (5) rs2134297 (Chr 18, nearest gene = *DCC*) (see [Table 2](#pmed.1002487.t002){ref-type="table"} for additional details).

Modest genetic enrichment between immune-mediated disease and PSP, CBD, and ALS {#sec017}
-------------------------------------------------------------------------------

To evaluate the specificity of the shared genetic overlap between FTD and immune-mediated disease, we also evaluated overlap between the 6 immune-mediated diseases and CBD, PSP, and ALS. For CBD and PSP, a few of the immune-mediated diseases produced genetic enrichment comparable to that seen for FTD ([S1](#pmed.1002487.s002){ref-type="supplementary-material"}--[S3](#pmed.1002487.s004){ref-type="supplementary-material"} Figs; [S2](#pmed.1002487.s012){ref-type="supplementary-material"}--[S4](#pmed.1002487.s014){ref-type="supplementary-material"} Tables). For example, we found 150-fold genetic enrichment between CBD and CeD and 180-fold enrichment between PSP and RA. In contrast, we found minimal enrichment between ALS and the immune-mediated diseases tested, with the highest levels of enrichment between ALS and RA (up to 20-fold) and between ALS and CeD (up to 15-fold).

At a conjunction FDR \< 0.05, we identified several SNPs associated with both immune-mediated disease and CBD, PSP, or ALS ([S4](#pmed.1002487.s005){ref-type="supplementary-material"}--[S6](#pmed.1002487.s007){ref-type="supplementary-material"} Figs; [S2](#pmed.1002487.s012){ref-type="supplementary-material"}--[S4](#pmed.1002487.s014){ref-type="supplementary-material"} Tables). Few of the SNPs shared between CBD, PSP, or ALS and immune-mediated disease mapped to the *HLA* region. Only 2 PSP--immune SNPs mapped to the region of *MLN* and *IRF4* on Chr 6, and no CBD--immune or ALS--immune SNPs mapped to the *HLA* region ([S4](#pmed.1002487.s005){ref-type="supplementary-material"}--[S6](#pmed.1002487.s007){ref-type="supplementary-material"} Figs; [S2](#pmed.1002487.s012){ref-type="supplementary-material"}--[S4](#pmed.1002487.s014){ref-type="supplementary-material"} Tables).

Beyond the *HLA* region, we found several overlapping loci between the immune- mediated diseases and CBD, PSP, and ALS ([S4](#pmed.1002487.s005){ref-type="supplementary-material"}--[S6](#pmed.1002487.s007){ref-type="supplementary-material"} Figs; [S2](#pmed.1002487.s012){ref-type="supplementary-material"}--[S4](#pmed.1002487.s014){ref-type="supplementary-material"} Tables). For PSP, these were (1) rs7642229 with CeD (Chr 3, nearest gene = *XCR1*, FDR = 1.74 × 10^−2^); (2) rs11718668 with CeD (Chr 3, nearest gene = *TERC*, FDR = 3.00 × 10^−2^); (3) rs12203592 with CeD (Chr 6, nearest gene = *IRF4*, FDR = 4.17 × 10^−2^); (4) rs1122554 with RA (Chr 6, nearest gene = *MLN*, FDR = 2.09 × 10^−2^); and (5) rs3748256 with RA (Chr 11, nearest gene = *FAM76B*, FDR = 2.09 × 10^−2^). For ALS, these were (1) rs3828599 with CeD (Chr 5, nearest gene = *GPX3*, FDR = 2.27 × 10^−2^) and (2) rs10488631 with RA (Chr 7, nearest gene = *TNPO3*, FDR = 3.42 × 10^−2^).

*cis*-eQTL expression {#sec018}
---------------------

To investigate whether shared FTD--immune SNPs modify gene expression, we evaluated *cis-*eQTLs in both brain and blood tissue types. At a previously established conservative Bonferroni-corrected *p*-value \< 3.9 × 10^−5^ \[[@pmed.1002487.ref034]\], we found significant *cis*-associations between shared SNPs and genes in the *HLA* region on Chr 6 in peripheral blood mononuclear cells, lymphoblasts, and the human brain (see [S5 Table](#pmed.1002487.s015){ref-type="supplementary-material"} for gene expression associated with each SNP). We also found that rs199533 and rs17572851 on Chr 17 were significantly associated with *MAPT* (*p* = 2 × 10^−12^) expression in the brain. Beyond the *HLA* and *MAPT* regions, notable *cis*-eQTLs included rs10784359 and *LRRK2* (*p* = 1.40 × 10^−\ 7^) and rs2192493 and *TBKBP1* (*p* = 1.29 × 10^−6^) (see [S5 Table](#pmed.1002487.s015){ref-type="supplementary-material"}).

Protein--protein and co-expression networks {#sec019}
-------------------------------------------

We found physical interaction and gene co-expression networks for the FTD--immune pleiotropic genes with significant *cis*-eQTLs (at a Bonferroni-corrected *p*-value \< 3.9 × 10^−5^). We found robust co-expression between various *HLA* classes, further suggesting that large portions of the *HLA* region, rather than a few individual loci, may be involved with FTD ([Fig 4](#pmed.1002487.g004){ref-type="fig"}; [S6 Table](#pmed.1002487.s016){ref-type="supplementary-material"}). Interestingly, we found that several non-*HLA* functionally expressed FTD--immune genes, namely, *LRRK2*, *PGBD5*, and *TBKBP1*, showed co-expression with *HLA*-associated genes ([Fig 4](#pmed.1002487.g004){ref-type="fig"}).

![Network interaction graph predominantly illustrating co-expression and shared protein domains for functionally expressed pleiotropic genes between frontotemporal dementia (FTD) and immune-related diseases.](pmed.1002487.g004){#pmed.1002487.g004}

Genetic expression in FTD brains compared to controls {#sec020}
-----------------------------------------------------

To investigate whether the FTD--immune pleiotropic genes with significant *cis*-eQTLs are differentially expressed in FTD brains, we compared gene expression in FTD-U brains to that in brains from neurologically healthy controls. We found significantly different levels of *HLA* gene expression in FTD-U brains compared to control brains ([Table 3](#pmed.1002487.t003){ref-type="table"}). This was true of FTD-U brains regardless of progranulin gene (*GRN*) mutation status. In spite of the fact that the FTD GWAS used to identify these genes was based on patients with sporadic FTD (without *GRN* mutations), *GRN* mutation carriers showed the greatest differences in *HLA* gene expression ([Fig 5](#pmed.1002487.g005){ref-type="fig"}; [Table 3](#pmed.1002487.t003){ref-type="table"}). These findings are compatible with prior work showing microglial-mediated immune dysfunction in *GRN* mutation carriers \[[@pmed.1002487.ref003]\].

![Pleiotropic genes between frontotemporal dementia (FTD) and immune-related diseases are elevated in brains of patients with FTD with *GRN* mutation.\
Expression for the genes with the largest effect sizes are plotted: (A) *HLA-A*, (B) *HLA-C*, (C) *HLA-DRQ*, and (D) *HLA-DRA*. Expression values were obtained from GSE13162 for FTD-U brains with and without *GRN* mutations and neuropathology-free controls. Horizontal bar represents mean ± SEM.](pmed.1002487.g005){#pmed.1002487.g005}

10.1371/journal.pmed.1002487.t003

###### Genes associated with frontotemporal dementia (FTD) and immune-mediated disease differentially altered in patients with frontotemporal lobar degeneration with ubiquitinated inclusions (FTD-U) versus controls.

![](pmed.1002487.t003){#pmed.1002487.t003g}

  Gene                       Control versus FTD-U *p*-value   Control versus *GRN*+ *p*-value
  -------------------------- -------------------------------- ---------------------------------
  *AOAH*                     0.631                            **0.013**
  *HLA-A*                    0.622                            **0.004**
  *HLA-C*                    0.372                            **0.002**
  *HLA-F*                    0.592                            **0.001**
  *HLA-DRA (LOC101060835)*   **0.017**                        **0.008**
  *HLA-DRQ (HLA-DQB1)*       **0.009**                        **0.001**
  *MAPT*                     0.376                            0.090
  *TBKBP1*                   **0.005**                        0.108
  *PGBD5*                    0.528                            **0.016**
  *LRRK2*                    N/A                              N/A

*p-*Values ≤ 0.05 are in bold.

N/A, not available.

Microglial enrichment {#sec021}
---------------------

For the FTD--immune pleiotropic genes with significant *cis*-eQTLs, across different central nervous system (CNS) cell types, we found significantly greater expression within microglia compared to neurons or fetal astrocytes ([Fig 6A](#pmed.1002487.g006){ref-type="fig"}; [Table 4](#pmed.1002487.t004){ref-type="table"}). Interestingly, *HLA* genes showed the greatest degree of differential expression. Four of the FTD--immune *HLA*-associated genes, namely *HLA-DRA*, *AOAH*, *HLA-A*, and *HLA-C*, showed highest expression in microglia (ranging from 10 to 60 fragments per kilobase of transcript per million; see [Fig 6B](#pmed.1002487.g006){ref-type="fig"}). In addition, *MAPT* was predominantly expressed in neurons, *LRRK2* in microglia, *PGBD5* in neurons, and *TBKBP1* in fetal astrocytes (Figs [6B](#pmed.1002487.g006){ref-type="fig"} and [S7](#pmed.1002487.s008){ref-type="supplementary-material"}--[S9](#pmed.1002487.s010){ref-type="supplementary-material"}).

![Microglia enrichment in genes associated with frontotemporal dementia (FTD) and immune-mediated disease.\
FTD--immune genes were analyzed to determine the cell type in which each gene was most highly expressed \[[@pmed.1002487.ref032]\]. (A) Bar plots showing the relative number of genes most highly expressed in each cell type. No genes were most highly expressed in endothelial cells or oligodendrocytes. See [Table 4](#pmed.1002487.t004){ref-type="table"} for individual gene names. (B) Individual bar plots showing cell-type-specific expression for genes with the largest effect size. Note that the horizontal scale is not the same in all the plots. FPKM, fragments per kilobase of transcript per million.](pmed.1002487.g006){#pmed.1002487.g006}

10.1371/journal.pmed.1002487.t004

###### Enrichment of genes associated with frontotemporal dementia (FTD) and immune-mediated disease in microglia compared with other central nervous system cells.

![](pmed.1002487.t004){#pmed.1002487.t004g}

  Gene          Most enriched cell type
  ------------- -------------------------
  *AOAH *       Microglia/macrophage
  *HLA-A *      Microglia/macrophage
  *HLA-C *      Microglia/macrophage
  *HLA-F *      Neurons
  *HLA-DRA *    Microglia/macrophage
  *HLA-DRQ *    Not found
  *LRRC37A3 *   Microglia/macrophage
  *MAPT *       Neurons
  *TRAM2*       Fetal astrocytes

No genes were most highly expressed in endothelial cells or oligodendrocytes.

Discussion {#sec022}
==========

We systematically assessed genetic overlap between 4 FTD-related disorders and several immune-mediated diseases. We found extensive genetic overlap between FTD and immune-mediated disease particularly within the *HLA* region on Chr 6, a region rich in genes associated with microglial function. This genetic enrichment was specific to FTD and did not extend to CBD, PSP, or ALS. Further, we found that shared FTD--immune gene variants were differentially expressed in FTD patients compared with controls, and in microglia compared with other CNS cells. Beyond the *HLA* region, by leveraging statistical power from large immune-mediated GWASs, we detected novel candidate FTD associations requiring validation within *LRRK2*, *TBKBP1*, and *PGBD5*. Considered together, these findings suggest that various microglia and inflammation-associated genes, particularly within the *HLA* region, may play a critical and selective role in FTD pathogenesis.

By combining GWASs from multiple studies and applying a pleiotropic approach, we identified genetic variants jointly associated with FTD-related disorders and immune-mediated disease. We found that the strength of genetic overlap with immune-mediated disease varies markedly across FTD-related disorders, with the strongest pleiotropic effects associated with FTD, followed by CBD and PSP, and the weakest pleiotropic effects associated with ALS. We identified 8 FTD- and immune-associated loci that mapped to the *HLA* region, a concentration of loci that was not observed for the other disorders. Indeed, only 2 PSP--immune pleiotropic SNPs and no CBD--immune or ALS--immune pleiotropic SNPs mapped to the *HLA* region. Previous work has identified particular *HLA* genes associated with CBD, PSP, and ALS \[[@pmed.1002487.ref035],[@pmed.1002487.ref036]\]. In contrast, our current findings implicate large portions of the *HLA* region in the pathogenesis of FTD. Together, these results suggest that each disorder across the larger FTD spectrum has a unique relationship with the *HLA* region.

Our results also indicate that functionally expressed FTD--immune shared genetic variants are differentially expressed in FTD brains compared to controls and in microglia compared to other CNS cell types ([Fig 6](#pmed.1002487.g006){ref-type="fig"}). Microglia play a role in the pathophysiology of *GRN*+ FTD. Progranulin is expressed in microglia \[[@pmed.1002487.ref037]\], and *GRN* haploinsufficiency is associated with abnormal microglial activation and neurodegeneration \[[@pmed.1002487.ref003]\]. It is perhaps expected, therefore, that *GRN+* brains show differential expression of FTD--immune genes, even though these genetic variants were derived from a GWAS of patients with sporadic FTD (who lack *GRN* or other established FTD mutations). More surprising is the presence of similar enrichment in *GRN*− brains, suggesting that dysfunction of microglial-centered immune networks may be a common feature of FTD pathogenesis.

By leveraging statistical power from the large immune-mediated GWASs, we identified novel candidate FTD associations requiring validation within *LRRK2*, *TBKBP1*, and *PGBD5* and confirmed previously shown FTD-associated signal within the *MAPT* region. *LRRK2* mutations are a cause of Parkinson disease \[[@pmed.1002487.ref038]\] and CD \[[@pmed.1002487.ref039]\]. We previously described a potential link between FTD and the *LRRK2* locus \[[@pmed.1002487.ref040]\], and another study using a small sample showed that *LRRK2* mutations may increase FTD risk \[[@pmed.1002487.ref041]\]. Together, these results suggest that the extended *LRRK2* locus might influence FTD despite common genetic variants within *LRRK2* not reaching genome-wide significance in a large FTD GWAS \[[@pmed.1002487.ref005]\]. We suggest that increased expression of *LRRK2* in microglia results in proinflammatory responses, possibly by modulating TNF-alpha secretion \[[@pmed.1002487.ref042]\]. *TBKBP1* also modulates TNF-alpha signaling by binding to *TBK1 (TANK binding kinase 1)* \[[@pmed.1002487.ref043]\]; rare pathogenic variants in *TBK1* cause FTD-ALS \[[@pmed.1002487.ref044]--[@pmed.1002487.ref046]\]. Importantly, elevated CSF levels of TNF-alpha are a core feature of FTD \[[@pmed.1002487.ref006],[@pmed.1002487.ref047]\]. Building on these findings, in our bioinformatics "network"-based analysis, we found that both *LRRK2* and *TBKBP1* interact with genes within the *HLA* region ([Fig 4](#pmed.1002487.g004){ref-type="fig"}). Further, physical interactions between *MAPT* and the *HLA* network are compatible with research suggesting that under different conditions reactive microglia can either drive or mitigate tau pathology \[[@pmed.1002487.ref048],[@pmed.1002487.ref049]\]. *MAPT* mutations, which disrupt the normal binding of tau protein to tubulin, account for a large proportion of familial FTD cases \[[@pmed.1002487.ref050]\]. Together, these findings suggest that *LRRK2*, *TBKBP1*, and *MAPT* may, at least in part, influence FTD pathogenesis via *HLA*-related mechanisms.

This study has limitations. Particularly, in the original datasets that form the basis of our analysis, diagnosis of FTD was established clinically. Given the clinical overlap among neurodegenerative diseases, we cannot exclude the potential influence of clinical misdiagnosis. As such, our findings would benefit from confirmation in large pathologically confirmed cohorts. In addition, given the complex interconnectedness of the *HLA* region (see [Fig 4](#pmed.1002487.g004){ref-type="fig"}), we also were not able to define the specific gene or genes on Chr 6 responsible for our pleiotropic signal. However, given the number of *HLA* loci associated with increased FTD risk, it may be the case that no single *HLA* variant will be clinically informative; rather, an *additive combination* of these microglia-associated genetic variants may better inform FTD risk. This possibility is supported by our observation that the expression levels of FTD-immune shared genetic variants differ *on average* between FTD brains and controls, but with considerable overlap between the two groups, again suggesting that no single variant is likely to be the determinant of FTD risk ([Fig 5](#pmed.1002487.g005){ref-type="fig"}). Further, we acknowledge the lack of transcriptomic and epigenetic data that would help to identify possible causal associations and mechanisms driving our pleotropic signal.

In conclusion, across a large cohort (total *n* = 192,886 cases and controls), we used pleiotropy between FTD-related disorders and immune-mediated disease to identify several genes within the *HLA* region that are expressed within microglia and differentially expressed in the brains of patients with FTD. Building on prior work \[[@pmed.1002487.ref006],[@pmed.1002487.ref007]\], our results support a disease model in which immune dysfunction is central to the pathophysiology of a subset of FTD cases. These findings have important implications for future work in FTD focused on monitoring microglial activation as a marker of disease progression and investigating anti-inflammatory treatments as modifiers of disease outcome.
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Click here for additional data file.

###### Fold enrichment plots of enrichment versus nominal −log~10~(*p*)-values (corrected for inflation) in corticobasal degeneration (CBD) below the standard genome-wide association study threshold of *p* \< 5 × 10^−8^ as a function of significance of association with 6 immune-mediated diseases.

The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of −log~10~(*p*) \> 0, −log~10~(*p*) \> 1, and −log~10~(*p*) \> 2 correspond to *p* \< 1, *p* \< 0.1, and *p* \< 0.01, respectively. The dark blue line indicates all SNPs.
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Click here for additional data file.

###### Fold enrichment plots of enrichment versus nominal −log~10~(*p*)-values (corrected for inflation) in progressive supranuclear palsy (PSP) below the standard genome-wide association study threshold of *p* \< 5 × 10^−8^ as a function of significance of association with 6 immune-mediated diseases.

The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of −log~10~(*p*) \> 0, −log~10~(*p*) \> 1, and −log~10~(*p*) \> 2 correspond to *p* \< 1, *p* \< 0.1, and *p* \< 0.01, respectively. The dark blue line indicates all SNPs.
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Click here for additional data file.

###### Fold enrichment plots of enrichment versus nominal −log~10~(*p*)-values (corrected for inflation) in amyotrophic lateral sclerosis (ALS) below the standard genome-wide association study threshold of *p* \< 5 × 10^−8^ as a function of significance of association with 6 immune-mediated diseases.

The 6 immune-mediated diseases are Crohn disease (CD), ulcerative colitis (UC), type 1 diabetes (T1D), rheumatoid arthritis (RA), celiac disease (CeD), and psoriasis (PSOR). The levels of −log~10~(*p*) \> 0, −log~10~(*p*) \> 1, and −log~10~(*p*) \> 2 correspond to *p* \< 1, *p* \< 0.1, and *p* \< 0.01, respectively. The dark blue line indicates all SNPs.
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Click here for additional data file.

###### "Conjunction" Manhattan plot of conjunction and conditional −log~10~(FDR) values for corticobasal degeneration (CBD) given 6 immune-mediated diseases.

The 6 immune-mediated diseases are Crohn disease (CD; CBD\|CD, red), ulcerative colitis (UC, CBD\|UC, orange), type 1 diabetes (T1D, CBD\|T1D, teal), rheumatoid arthritis (RA, CBD\|RA, green), celiac disease (CeD, CBD\|CeD, magenta), and psoriasis (PSOR, CBD\|PSOR, blue). SNPs with conditional and conjunction −log~10~(FDR) \> 1.3 (i.e., FDR \< 0.05) are shown with large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each locus.
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###### "Conjunction" Manhattan plot of conjunction and conditional −log~10~(FDR) values for progressive supranuclear palsy (PSP) given 6 immune-mediated diseases.

The 6 immune-mediated diseases are Crohn disease (CD; PSP\|CD, red), ulcerative colitis (UC, PSP\|UC, orange), type 1 diabetes (T1D, PSP\|T1D, teal), rheumatoid arthritis (RA, PSP\|RA, green), celiac disease (CeD, PSP\|CeD, magenta), and psoriasis (PSOR, PSP\|PSOR, blue). SNPs with conditional and conjunction −log~10~(FDR) \> 1.3 (i.e., FDR \< 0.05) are shown with large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each locus.
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###### "Conjunction" Manhattan plot of conjunction and conditional −log~10~(FDR) values for amyotrophic lateral sclerosis (ALS) given 6 immune-mediated diseases.

The 6 immune-mediated diseases are Crohn disease (CD; ALS\|CD, red), ulcerative colitis (UC, ALS\|UC, orange), type 1 diabetes (T1D, ALS\|T1D, teal), rheumatoid arthritis (RA, ALS\|RA, green), celiac disease (CeD, ALS\|CeD, magenta), and psoriasis (PSOR, ALS\|PSOR, blue). SNPs with conditional and conjunction −log~10~(FDR) \> 1.3 (i.e., FDR \< 0.05) are shown with large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block, and this SNP was annotated with the closest gene, which is listed above the symbols in each locus.
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###### Individual bar plots showing cell-type-specific expression for *LRRK2*.
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###### Individual bar plots showing cell-type-specific expression for *PGBD5*.
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###### Individual bar plots showing cell-type-specific expression for *TBKBP1*.
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###### Summary-data-based Mendelian randomization results.
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###### Overlapping loci between CBD and immune-mediated diseases at a conjunction FDR \< 0.05.

(DOCX)

###### 

Click here for additional data file.

###### Overlapping loci between PSP and immune-mediated diseases at a conjunction FDR \< 0.05.
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###### Overlapping loci between ALS and immune-mediated diseases at a conjunction FDR \< 0.05.
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###### *cis*-eQTLs between FTD and immune-mediated disease shared risk SNPs and associated genes across a variety of tissues.
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###### Physical interaction and gene co-expression networks for the pleiotropic genes with significant *cis*-eQTLs.
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ALS

:   amyotrophic lateral sclerosis

CBD

:   corticobasal degeneration

CD

:   Crohn disease

CeD

:   celiac disease

Chr

:   Chromosome

*cis*-eQTL

:   *cis*-expression quantitative trait locus

CNS

:   central nervous system

FDR

:   false discovery rate

FTD

:   frontotemporal dementia

FTD-U

:   frontotemporal lobar degeneration with ubiquitinated inclusions

GWAS

:   genome-wide association study

IFGC

:   International FTD-Genomics Consortium

LD

:   linkage disequilibrium

NIAGADS

:   National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site

PSOR

:   psoriasis; PSP, progressive supranuclear palsy

RA

:   rheumatoid arthritis

SMR

:   summary-data-based Mendelian randomization

SNP

:   single nucleotide polymorphism

T1D

:   type 1 diabetes

UC

:   ulcerative colitis
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